The AHA Tuesday responded to a Centers for Medicare & Medicaid Services request for information regarding whether the agency should include exceptions to the electronic prescribing of controlled substances requirements in the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act.

The comments also respond to CMS’ question of whether it should impose penalties for noncompliance.

“While we do not oppose the general requirement for prescriptions for Schedule II-V controlled substances to be transmitted electronically, we are concerned with the timeline proposed for implementation as well as the potential for penalties for noncompliance within this timeline,” the AHA said. It urged CMS to approach the requirement “based on a holistic view of the full range of federal regulations that require hospital IT development, upgrade, testing and end-user training, and proceed with a period of enforcement discretion and lack of penalties.”

Related News Articles

Headline
The Federal Trade Commission April 23 voted 3-2 to issue a final rule that would ban as an unfair method of competition contractual terms that prohibit workers…
Headline
The Department of Health & Human Services’ Office for Civil Rights April 22 released a final rule prohibiting entities regulated by the HIPAA Privacy Rule…
Headline
Senate Health, Education, Labor & Pensions Committee Ranking Member Bill Cassidy, R-La., Feb. 21 released a report proposing ways to modernize the existing…
Headline
The National Institute of Standards and Technology this week released updated guidance to help HIPAA-covered entities and business associates assess and manage…
Blog
A recent Modern Healthcare article misleadingly suggests that hospitals and health systems provided less charity care between 2020 and 2023. The truth is much…
Headline
The Department of Health and Human Services’ Office for Civil Rights Oct. 18 released a resource for health care providers who choose to educate patients about…